Diagnostic value of serum vascular endothelial growth factor and interleukin-17 in primary hepatocellular carcinoma

BACKGROUND Despite significant advancements in the medical treatment of primary hepato-cellular carcinoma(PHC)in recent years,enhancing therapeutic effects and im-proving prognosis remain substantial challenges worldwide.AIM To investigate the expression levels of serum vascular endothelial growth factor(VEGF)and interleukin(IL)-17 in patients with PHC and evaluate their diagnostic value while exploring their relationship with patients’clinical characteristics.METHODS The study included 50 patients with confirmed PHC who visited Wuhan Han-yang Hospital from January 2021 to January 2022,and 50 healthy individuals from the same period served as the control group.Serum VEGF and IL-17 levels in both groups were measured by Enzyme-Linked Immunosorbent Assay,and their diagnostic value was assessed using receiver operating characteristic(ROC)curves.Pearson correlation analysis was performed to examine the relationship between serum VEGF and IL-17 levels.Pathological data of the PHC patients were analyzed to determine the relationship between serum VEGF and IL-17 levels and pathological characteristics.RESULTS Serum VEGF and IL-17 levels were significantly higher in the study group com-pared to the control group(P<0.05).No significant association was observed between serum VEGF and IL-17 levels and gender,age,combined cirrhosis,tumor diameter,or degree of differentiation(P>0.05).However,there was a significant relationship between clinical TNM stage,tumor metastasis,and serum VEGF and IL-17 levels(P<0.05).Correlation analysis revealed a positive correlation between serum VEGF and IL-17(P<0.05).ROC analysis demonstrated that both serum VEGF and IL-17 had good diagnostic efficacy for PHC.CONCLUSION Serum VEGF and IL-17 levels were significantly higher in PHC patients compared to healthy individuals.Their levels were closely related to pathological features such as tumor metastasis and clinical TNM stage,and there was a significant positive correlation between VEGF and IL-17.These biomarkers may serve as valuable reference in-dicators for the early diagnosis and treatment guidance of PHC.

Increased serum levels of soluble CD146 and vascular endothelial growth factor receptor 2 in patients with exudative age-related macular degeneration

AIM: To investigate serum levels of soluble CD146(s CD146) and vascular endothelial growth factor receptor 2(VEGFR2) in patients with age-related macular degeneration(AMD). METHODS: Eighty-eight patients with exudative AMD and 45 sex-and age-matched healthy controls were enrolled in this study conducted in China. Serum samples was obtained from the patients with exudative AMD and from the controls. Serum sCD146 and VEGFR2 protein levels were measured using an enzyme-linked immunosorbent assay.RESULTS: We found that serum sCD146 and VEGFR2 protein levels were significantly higher in the patients with exudative AMD group than in the controls(t=3.859, P<0.001 and t=3.829, P<0.001, respectively). Serum sCD146 levels were significantly higher in patients with classic choroidal neovascularization(CNV) than in those with occult CNV(t=9.899, P<0.001). There was a significant difference in the trend for exudative AMD in the highest versus lowest quartile of circulating sCD146 levels(χ2=10.29, P=0.001). The receiver operating characteristic curve analysis showed that the area under the curve was 0.696 for s CD146(95%CI: 0.601-0.791) with an optimum diagnostic cut-off value of 157.16 ng/mL, a sensitivity of 55.7%, and a specificity of 82.2%.CONCLUSION: The serum sCD146 level increases and may be a biomarker for exudative AMD.

Clinical significance of serum vascular endothelial growth factor in advanced malignant tumors

Objective： To elucidate the clinical significance of serum vascular endothelial growth factor （VEGF） level in pa- tients with advanced cancer. Methods： Enzyme linked immunosorbent assay （ELISA） was used to determine the serum VEGF concentration in 40 patients with advanced cancer [non-small cell rung cancer （NSCLC）, esophageal cancer （EC） and nasopharyngeal carcinoma （NPC）] before and after chemotherapy and 10 healthy volunteers as control group. Results： The serum VEGF concentrations in 40 cases of advanced cancer patients were significantly higher than those of 10 healthy control cases [（477.07 ± 374.10 ） pg/mL vs （139.09 ± 133.41 ） pg/mL; P = 0.016]. The serum VEGF concentrations in patients with NSCLC, EC and NPC were （518.53 _± 378.99） pg/mL, （399.21 ± 393.69） pg/mL and （500.68 ± 348.48） pg/mL, respectively. The differences were all statistically significant as compared with healthy control group （P values were 0.011,0.044 and 0.019, respectively）. The serum VEGF concentrations of the patients in response to chemotherapy was significantly lower than those of the same patients before they undergoing chemotherapy [（400.41 ± 332.84） pg/mL vs （777.10 ± 666.01） pg/mL; P = 0.034]. Conclusion： The serum VEGF level might be a novel and promising tumor marker of advanced malignancies and a predictor of disease progression, prognosis and therapeutic efficacy,

Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients

AIM: To evaluate vascular endothelial growth factor(VEGF) and tryptase in hepatocellular cancer(HCC)before and after trans-arterial chemoembolization(TACE).METHODS: VEGF and tryptase serum concentrations were assessed from 71 unresectable HCC patients before and after hepatic TACE performed by binding DC-Beads?to doxorubicin. VEGF levels were examined for each serum sample using the Quantikine Human VEGF-enzyme-linked immuno-absorbent assay(ELISA),whereas tryptase serum concentrations were assessed for each serum sample by means of fluoro-enzyme immunoassay(FEIA) using the Uni-CAP100 tool.Differences between serum VEGF and tryptase values before and after TACE were evaluated using Student t test. Person's correlation was used to assess the degree of association between the two variables.RESULTS: VEGF levels and serum tryptase in HCCpatients before TACE had a mean value and standard deviation(SD) of 114.31 ± 79.58 pg/mL and 8.13± 3.61 μg/L, respectively. The mean levels and SD of VEGF levels and serum tryptase in HCC patients after TACE were 238.14 ± 109.41 pg/mL and 4.02 ±3.03 μg/L. The changes between the mean values of concentration of VEGF and tryptase before treatment and after treatment was statistically significant(P <0.000231 and P < 0.00124, by Wilcoxon-Mann-Whitney respectively). A significant correlation between VEGF levels before and after TACE and between tryptase levels before and after TACE was demonstrated(r =0.68, P = 0.003; r = 0.84, P = 0.000 respectively).CONCLUSION: Our pilot results suggest that the higher serum VEGF levels and the lower tryptase levels following TACE may be potential biomarkers changing in response to therapy.

Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion

Objective:To evaluate the diagnostic value of endostatin(ES),vascular endothelial growth factor (VEGF) and careinoembryonie antigen(CEA) in both serum and pleural effusion of lung cancer patients.Methods:Levels of ES,VEGF and CEA in 52 malignant pleural effusion due to lung cancer and 50 patients with non-malignant disease were measured by using sandwich enzymelinked immunosorbent assay and microparticle enzyme immunoassay.Results:The ES.VEGF and CEA levels in pleural effusion and serum,and their ratio(F/S) were higher in lung cancer group than that in benign group,and the differences were statistically significant(P【0.05).The diagnostic efficiency of ES+VEGF for lung cancer was superior to either single detection.The diagnostic efficiency of ES+VEGK+CEA was superior to either ES+VEGF or ES+CEA.Conclusions: The results suggest that ES,VEGF and CEA might be useful in the differentiation between benign and malignant pleural effusion due to lung cancer.In comparison with either single determination of concentration in serum or pleural fluid,the couiljined detection of two or three markers is of important clinical significance in the diagnosis of lung cancer.

Correlation of serum ICAM-1 and VEGF levels with microvascular injury in patients with senile diabetic retinopathy

Objective:To study the correlation between serum vascular endothelial growth factor (VEGF) and intercellular adhesion molecule (ICAM) -1 level and microvascular injury in elderly diabetic retinopathy, and provide reference for clinical diagnosis and treatment.Methods:A total of 268 diabetic patients in our hospital in October 2015 -2017 year in October, on the basis of fundus fluorescein angiography and fundus examination were divided into proliferative diabetic retinopathy group (PDR), background diabetic retinopathy group (BDR) and diabetic retinopathy group (NDR), and 100 healthy at the same time to participate in the examination of our hospital as the control group. The changes of ICAM-1, VEGF and nitric oxide (NO), von Willebrand factor (vWF), endothelin-1 (ET-1) and thrombomodulin (TM) and other vascular endothelial function indexes in four groups were compared.Results:NDR group, BDR group, PDR group, ICAM-1, VEGF, NO and vWF (except NDR group), four ET-1 TM and vascular endothelial function indexes were significantly higher than the control group, while the difference between NDR vWF group was not statistical significant;differences in ICAM-1, VEGF and NO, vWF, ET-1 and TM four vascular endothelial function index among NDR group, BDR group and PDR group were statistically significant. Compared with the two groups, four vascular endothelial function indexes of ICAM-1, VEGF and NO, vWF, ET-1 and TM in retinopathy group were significantly higher than those in control group. Conclusions:There is correlation between VEGF, ICAM-1 level and microvascular injury in senile diabetic retinopathy patients. The late progression of the disease is, the higher VEGF, ICAM-1, NO, vWF, ET-1 and TM of vascular endothelial damage indexes are.It can reflect the microcirculation the extent of injury and blood rheology, and change of coagulation mechanism. It is worthy for clinical reference.

子痫前期患者胎盘中EG-VEGF及其PROKR1和PROKR2的表达情况

目的探讨子痫前期(PE)患者血清、胎盘中内分泌腺源性血管内皮生长因子(EG-VEGF)、前动力蛋白1(PROK1)、前动力蛋白2(PROK2)的表达情况及其临床意义。方法选取2019年1月至2022年1月该院收治的100例PE患者作为研究组,依据病情严重程度分为轻度组和重度组,各50例。同时,选取同期行剖宫产手术的50例健康孕妇作为对照组。比较两组临床指标[γ-谷氨酰转移酶(GGT)、乳酸脱氢酶(LDH)、尿酸(UA)、收缩压、舒张压、血小板计数、新生儿体重、螺旋动脉管壁厚度、螺旋动脉管腔面积、丙二醛(MDA)、超氧化物歧化酶(SOD)、谷氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、尿素氮(BUN)]。对比分析不同组、不同病情严重程度患者血清、胎盘组织中EG-VEGF、PROKR1、PROKR2 mRNA水平。采用免疫组化法检测两组胎盘组织中EG-VEGF、PROKR1、PROKR2阳性表达率,分析研究组血清各指标与临床特征、病情严重程度相关性,以及检测不同新生儿结局的孕妇血清中各指标水平。采用受试者工作特征(ROC)曲线分析血清各指标水平对PE的诊断价值。结果与对照组比较,研究组收缩压、舒张压、血小板计数、螺旋动脉管壁厚度升高,GGT、LDH、UA、ALT、AST、MDA水平升高,新生儿体重、螺旋动脉管腔面积降低,BUN、SOD水平降低,差异均有统计学意义(P<0.05)。与对照组比较,研究组血清、胎盘组织中EG-VEGF、PROKR1、PROKR2 mRNA水平降低(P<0.05),且其水平与新生儿体重、螺旋动脉管腔面积、BUN、SOD呈正相关,而与收缩压、舒张压、螺旋动脉管壁厚度、GGT、LDH、ALT、MDA、病情严重程度呈负相关(P<0.05)。研究组EG-VEGF、PROKR1、PROKR2阳性表达率低于对照组(P<0.05);研究组发生新生儿不良结局的孕妇血清中EG-VEGF、PROKR1、PROKR2水平低于对照组(P<0.05)。EG-VEGF、PROKR1、PROKR2联合诊断PE的曲线下面积大于单项诊断(P<0.05)。结论PE患者血清、胎盘中EG-VEGF、PROKR1、PROKR2呈低表达,且与临床特征、病情严重程度、新生儿不良结局存在相关性,联合检测其水平可提高PE的诊断效能。

子宫内膜癌患者血清sVEGFR1、YKL-40、IGF-1表达水平及临床意义研究

目的探究子宫内膜癌患者血清可溶性血管内皮生长因子受体1(sVEGFR1)、甲壳质酶蛋白40(YKL-40)、胰岛素样生长因子1(IGF-1)表达水平及临床意义。方法择取本院100例子宫内膜癌患者作为观察组;另选取同期100例健康体检者作为对照组。比较两组sVEGFR1、YKL-40、IGF-1表达水平并分析观察组不同分期表达水平。结果观察组sVEGFR1表达水平较对照组低,YKL-40、IGF-1表达水平较对照组高,差异有统计学意义(P<0.05)。观察组Ⅰ~Ⅳ期sVEGFR1表达水平明显降低,YKL-40、IGF-1表达水平升高,差异有统计学意义(P<0.05)。结论在子宫内膜癌患者中,sVEGFR1、YKL-40、IGF-1均出现异常表达,不同分期患者存在较大差异,可为疾病诊断与分期提供可靠的数据参考。

基于ROC曲线分析子痫前期孕妇血清EG-VEGF、NLR、PLR表达与病情严重程度的相关性

目的探讨子痫前期孕妇血清内分泌腺源性血管内皮生长因子(EG-VEGF)、中性粒细胞淋巴细胞比值(NLR)、血小板淋巴细胞比值(PLR)表达与病情严重程度的相关性。方法回顾性分析2021年10月~2023年3月在承德市中心医院妇儿院区产检的90例孕妇临床资料,根据是否患有子痫前期进行分组,将健康正常的30例孕妇纳入健康对照组,将确诊为子痫前期的60例孕妇纳入观察组,且观察组根据子痫前期严重程度分为轻度组(n=30)和重度组(n=30),比较健康对照组和观察组、轻度组和重度组的血清EG-VEGF、NLR、PLR表达水平,并应用ROC曲线分析血清EG-VEGF、NLR、PLR诊断子痫前期和评价病情严重程度的效能。结果观察组的血清EG-VEGF、NLR高于健康对照组[(53.65±17.46)pg ml vs.(28.93±9.37)pg ml、(3.15±1.02)vs.(2.12±0.67)],PLR低于健康对照组[(98.53±21.86)vs.(115.31±18.36)],差异有统计学意义(t=7.237、5.010、3.613,P<0.05)。经ROC曲线分析发现,血清EG-VEGF、NLR、PLR诊断子痫前期效能良好(P<0.05)。重度组的血清EG-VEGF、NLR高于轻度组[(57.93±13.19)pg ml vs.(49.63±15.63)pg ml、(3.40±0.95)vs.(2.93±0.71)],PLR低于轻度组[(163.72±35.41)vs.(146.70±28.63)],差异有统计学意义(t=2.223、2.171、2.047,P<0.05)。经ROC曲线分析,发现血清EG-VEGF、NLR、PLR评价子痫前期病情严重程度的效能良好(P<0.05)。结论子痫前期孕妇血清EG-VEGF、NLR呈高表达水平,PLR呈低水平表达,且病情越严重的孕妇血清EG-VEGF、NLR越高,PLR越低,且经ROC分析血清EG-VEGF、NLR、PLR在子痫前期和病情严重程度诊断评价方面效能良好。

生存素及血管内皮生长因子表达与反复自然流产的关系探讨

目的探讨生存素及血管内皮生长因子表达与反复自然流产的关系。方法选择60例反复自然流产患者作为观察组,同期60例人工流产患者作为对照组。对两组绒毛组织及血清中生存素及血管内皮生长因子表达进行测定。比较两组血清生存素及血管内皮生长因子表达水平,绒毛组织生存素及血管内皮生长因子阳性率。结果观察组血清生存素、血管内皮生长因子表达水平分别为(12.40±4.42)、(11.43±4.09)pg/ml,低于对照组的(18.75±2.49)、(18.06±3.41)pg/ml,差异具有统计学意义(P<0.05)。观察组绒毛组织生存素、血管内皮生长因子阳性率分别为31.67%、35.00%,均低于对照组的73.33%、76.67%,差异具有统计学意义(P<0.05)。结论反复自然流产患者的绒毛组织中生存素及血管内皮生长因子阳性率低于健康人,且血清中生存素及血管内皮生长因子表达水平低于健康人,生存素及血管内皮生长因子可能在反复自然流产的发生及发展中具有重要作用。

血清HIF-1α、LP(a)、VEGF、LP-PLA2水平与冠心病病情的相关性研究

目的分析血清低氧诱导因子-1α(HIF-1α)、脂蛋白a[LP(a)]、血管内皮生长因子(VEGF)、脂蛋白相关磷脂酶A2(LP-PLA2)在监测冠心病病情方面的临床意义。方法回顾性分析我院收治的冠心病患者192例,依据冠脉造影检查结果对其进行分组,分为单支、双支、多支冠脉病变组以及轻度、中度以及重度狭窄组;另选健康体检者为对照组;对比不同检查结果下冠心病患者、对照组之间的血清HIF-1α、LP(a)、VEGF、LP-PLA2水平,分析各指标间的差异以及对病情程度的监测意义。结果比较不同冠脉分支组的血清HIF-1α、LP(a)、VEGF、LP-PLA2水平,病变组均高于对对照组,其中多支病变组水平最高,单支病变组最低;不同病情程度的指标水平对比,病变组高于对照组,重度组水平高于中度组,中度组高于轻度组,差异具有统计学意义(P<0.05);ROC曲线分析,血清HIF-1α、LP(a)、VEGF、LP-PLA2评估中重度冠心病的AUC分别为0.865、0.751、0.799、0.782,联合评估AUC为0.887。结论血清HIF-1α、LP(a)、VEGF、LP-PLA2水平变化与冠心病患者病情变化相关,临床可通过检测这4项指标变化评估冠心病患者具体病情。

卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌的疗效及对患者血清肿瘤标志物、血管内皮生长因子和基质金属蛋白酶-9的影响

目的探讨卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及对患者血清肿瘤标志物、血管内皮生长因子(VEGF)和基质金属蛋白酶-9(MMP-9)的影响。方法选取2019年1月至2021年12月淄博岜山万杰医院肿瘤科收治的62例晚期NSCLC患者作为研究对象,随机分为观察组与对照组,每组31例。对照组给予依托泊苷联合顺铂化疗方案,观察组在对照组基础上联合卡瑞利珠单抗治疗。比较两组临床疗效、治疗前后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原72-4(CA72-4)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]、VEGF和MMP-9水平。结果观察组治疗总有效率为54.84%,高于对照组的29.03%,差异有统计学意义(P<0.05);治疗后,两组CEA、CA72-4和CYFRA21-1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组VEGF、MMP-9水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论卡瑞利珠单抗联合化疗可有效提高晚期NSCLC患者近期疗效,降低血清肿瘤标志物水平,抑制VEGF和MMP-9表达,有效防止肿瘤转移和侵袭,效果优于单纯化疗。

血清INHB、IGF-1、VEGF、E_(2)在多囊卵巢综合征患者中的表达及临床意义

目的探究多囊卵巢综合征患者血清抑制素B(Serum Inhibin B,INHB)、血管内皮生长因子(Vascular Endothelial Growth Factors,VEGF)、类胰岛素样生长因子1(Insulin-like Growth Factor-1,IGF-1)、雌二醇(Es⁃tradiol,E2)的表达及临床意义。方法选取2021年5月—2022年7月呼伦贝尔市妇幼保健院收治的40例多囊卵巢综合征患者为研究组,选取40名同期健康体检者为对照组,对比血清指标检测水平、不同严重程度多囊卵巢综合征血清指标的表达量差异、研究胰岛素抵抗指数与血清INHB、IGF-1、VEGF、E2的相关性。结果研究组的INHB(185.96±42.05)pg/mL、VEGF(913.46±94.36)ng/L、IGF-1(164.23±18.54)ng/mL、E2(198.28±34.62)pmol/L水平均高于对照组,差异有统计学意义(t=10.226、15.103、12.710、4.657,P均<0.05)。研究组重度患者的血清INHB、IGF-1、VEGF、E2水平均高于轻度、中度患者,差异有统计学意义(P均<0.05)。血清指标INHB、IGF-1、VEGF、E2与多囊卵巢综合征患者疾病呈正相关(r=0.356、0.419、0.486、0.512,P均<0.05)。结论在多囊卵巢综合征中INHB、VEGF、IGF-1、E2均呈现高表达,能够为临床诊治多囊卵巢综合征提供客观依据。

Clinicopathologic significance of expression of nuclear factor-kB RelA and its target gene products in gastric cancer patients

AIM:To assess the prognostic significance of nuclear factor-kB (NF-kB) and its target genes in gastric cancer. METHODS:The tumor tissues of 115 patients with gastric cancer were immunohistochemically evaluated using monoclonal antibodies against NF-kB RelA. Preoperative serum levels of vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) were assessed via enzyme-linked immuno-sorbent assay. C-reactive protein (CRP) and serum amyloid A (SAA) were measured via immunotrubidimetry. RESULTS:Positive rate of NF-kB RelA was 42.6%. NF-kB RelA expression in tumor tissues was also related to serum levels of IL-6 (P = 0.044) and CRP (P = 0.010). IL-6, SAA, CRP were related to depth of invasion, VEGF and SAA were correlated with lymph node metastasis. IL-6, VEGF, SAA and CRP were related to the stage. Univariate analysis demonstrated that immunostaining of NF-kB RelA, levels of IL-6, VEGF, SAA were significantly related with both disease free survival and over-all survival (OS). Multivariate analysis verified that NF-kB RelA [hazard ratio (HR): 3.40, P = 0.024] and SAA (HR: 3.39, P = 0.045) were independently associated with OS. CONCLUSION: Increased expression of NF-kB RelA and high levels of serum SAA were associated with poor OS in gastric cancer patients.

子宫肌瘤患者超声弹性成像参数及血清miR-34a、sFlt-1表达及诊断价值

目的:探究经腹部超声弹性成像参数子宫动脉搏动指数(PI)、阻力指数(RI)、弹性应变力比值(SR)及血清miR-34a、sFlt-1在子宫肌瘤患者中的表达及诊断价值。方法:选取2021年4月-2022年4月本院收治的子宫肌瘤患者50例为子宫肌瘤组,正常体检健康女性50例为对照组,分析两组超声参数、miR-34a、sFLt-1、SR水平;观察miR-34a、sFLt-1与临床特征及与子宫肌瘤发病关系;探究经腹部超声弹性成像参数、miR-34a、sFLt-1对子宫肌瘤的诊断价值。结果:子宫肌瘤组PI、RI、miR-34a低于对照组,sFLt-1及SR高于对照组,且子宫肌瘤组中有阴道不规则出血患者血清miR-34a、sFLt-1表达异常更高(均P<0.05);miR-34a与子宫肌瘤发病率呈负相关,sFLt-1与子宫肌瘤发病率呈正相关;腹部超声弹性成像参数、血清miR-34a及sFLt-1均对子宫肌瘤有一定诊断价值,但各指标联合检测价值更高,曲线下面积0.901,诊断敏感度91.4%、特异性94.1%。结论:子宫肌瘤患者PI、RI、SR、miR-34a、sFLt-1均异常,miR-34a、sFLt-1与子宫肌瘤发病具相关性;腹部超声弹性成像参数联合血清miR-34a、sFLt-1检测对子宫肌瘤有较高诊断价值。

沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤的疗效及对患者血清VEGF水平的影响研究

目的探讨沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤的疗效及对患者血清VEGF水平的影响研究。方法选取2017年1月—2021年10月吉林省人民医院血液科收治的120例弥漫大B细胞淋巴瘤患者为研究对象,随机分为对照组和观察组,每组60例。对照组采取CHOP方案治疗,观察组采取沙利度胺联合CHOP方案治疗,对比两组患者的治疗效果以及血清VEGF水平变化情况。结果观察组患者的客观缓解率为93.33%,明显高于对照组的76.67%,差异有统计学意义(χ^(2)=6.535,P=0.010)。治疗前,两组患者的VEGF水平对比,差异无统计学意义(χ^(2)=0.146,P=0.883);治疗后,两组患者的VEGF水平均出现了降低,且观察组患者的VEGF水平更低,差异有统计学意义(χ^(2)=14.185,P<0.001)。观察组患者的不良反应发生率为30.00%,低于对照组的38.33%,但差异无统计学意义(P>0.05)。结论沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤可获得更好的治疗有效率,且可有效降低血清VEGF水平,同时也具有更好的安全性。

远端血管通路导管治疗急性脑梗死对血清金属基质蛋白酶-9、血管内皮生长因子的影响

目的:研究急性脑梗死(ACI)患者行远端血管通路导管治疗的效果。方法:选择70例ACI患者,按照随机数字表法分为导管组和支架组,每组35例。其中支架组采用支架取栓治疗,导管组采用远端血管通路导管抽吸取栓治疗,利用酶联免疫吸附法(ELISA)检测血清金属基质蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)水平,采用美国国立卫生研究院脑卒中量表(NIHSS)和日常生活能力量表(ADL)量表评价患者神经功能和日常生活能力恢复情况,比较两组不良反应发生率。结果:治疗前两组的MMP-9、VEGF水平差异无统计学意义(P>0.05),治疗后两组的MMP-9、VEGF水平均降低,并且导管组变化幅度大于支架组变化幅度,差异有统计学意义(P<0.05);治疗前两组的NIHSS、ADL评分差异无统计学意义(P>0.05),治疗后两组的NIHSS评分均降低,ADL评分均升高,并且导管组变化幅度大于支架组变化幅度,差异有统计学意义(P<0.05);两组主要不良事件包括动脉夹层、心肌梗死、消化出血,其中导管组不良事件发生率为7.5%,支架组不良事件发生率为25.00%,导管组不良事件占比更低,差异有统计学意义(P<0.05)。结论:远端血管通路导管治疗ACI患者可降低血清因子,改善患者神经功能和日常生活能力,避免发生不良事件。

消瘤汤对子宫肌瘤患者血清肿瘤标志物、雌激素及血管内皮生长因子水平的影响

目的分析消瘤汤辅助治疗对子宫肌瘤患者血清肿瘤标志物、雌激素及血管内皮生长因子(Vascular endothelial growth factor,VEGF)水平的影响。方法2018年12月—2020年12月收治的子宫肌瘤患者134例,根据治疗方法不同分为两组。对照组给予单独米非司酮治疗,试验组在对照组基础上给予消瘤汤辅助治疗,分析两组治疗后的临床疗效。结果两组治疗前子宫肌瘤和子宫体积组间比较,差异无统计学意义(P>0.05)。试验组治疗后子宫肌瘤体积(7.58±0.94)cm^(3)、子宫体积(67.35±10.75)cm^(3)低于对照组(P<0.05)。两组治疗前血清肿瘤标志物、雌激素、VEGF、血清核转录因子-κB p65(Nuclear transcription factor-κB,NF-κB p65)水平组间比较,差异无统计学意义(P>0.05)。试验组治疗后糖类抗原125(Carbohydrate antigen 125,CA125)、人附睾蛋白4(Human epididymis protein-4,HE4)、糖类抗原199(Carbohydrate antigen199,CA199)、雌激素、VEGF、NF-κB p65水平低于对照组(P<0.05)。结论消瘤汤辅助治疗对子宫肌瘤可降低血清肿瘤标志物、雌激素、VEGF、NF-κB p65的表达水平,缩小子宫肌瘤和子宫体积。

sflt-1及超声动脉血流参数预测子痫前期临床价值

目的:探究血清可溶性血管内皮生长因子受体-1(sflt-1)及超声动脉血流参数阻力指数(RI)、搏动指数(PI)及收缩期与舒张期峰值流速比(S/D)预测子痫前期(PE)临床价值。方法:2019年8月-2022年5月本院就诊的106例具备PE高危因素的孕妇纳为研究对象,采集孕16~20周外周静脉血,酶联免疫吸附法检测血清sflt-1水平,孕20~24周多普勒超声检测子宫动脉血流参数。确诊PE48例为PE组,血压正常58例为对照组,比较两组血清sflt-1及超声动脉血流参数,绘制受试者工作特征曲线(ROC),分析各指标预测PE价值。结果:PE组确诊时收缩压(SBP)、舒张压(DBP)、血白蛋白、血尿氮素水平均高于对照组,胎盘质量及新生儿出生体重均低于对照组(P<0.05)。PE组血清sflt-1(27.15±3.78 mg/L)、RI(0.92±0.18)、PI(1.52±0.21)、S/D(4.16±1.11)水平均高于对照组(5.49±1.14 mg/L、0.73±0.16、1.01±0.18、3.63±0.79)(P<0.05)。ROC分析,血清sflt-1预测PE价值与RI、PI相似,S/D预测价值最低,RI、PI、S/D联合预测PE的价值高于各参数指标,曲线下面积(AUC)=0.856;血清sflt-1、RI、PI、S/D联合预测效能最高,AUC=0.920。结论:PE患者血清sflt-1及彩色超声多普勒子宫动脉血流参数PI、RI、S/D水平均异常升高,各指标联合应用预测PE的效能较高,可作为临床筛查或预测PE提供参考指标。

吉非替尼联合新辅助化疗对ⅢA期EGFR突变型非小细胞肺癌患者血清肿瘤标志物和远期预后的影响

目的:探讨吉非替尼联合新辅助化疗对ⅢA期表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)患者血清肿瘤标志物和远期预后的影响。方法:选取2016年1月~2017年1月期间于某院行手术切除治疗的104例ⅢA期EGFR突变型NSCLC患者作为研究对象,按照随机数字表法分为对照组和研究组,每组52例。对照组术前给予紫杉醇+奈达铂新辅助化疗联合手术切除治疗,研究组在对照组基础上术前加用吉非替尼辅助化疗,两组患者术后2周均给予紫杉醇+奈达铂辅助化疗+普通外照射放疗+吉非替尼辅助靶向治疗。比较两组患者临床病理资料、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、血清铁蛋白(SF)]、血管内皮生长因子(VEGF)水平以及术后并发症发生情况,Kaplan-Meier生存分析比较两组患者术后5年无病生存率和总生存率。结果:治疗后,对照组血清SF水平较治疗前降低(P<0.05),研究组血清CEA、CA125、SF及VEGF水平较治疗前均降低(P<0.05);两组患者术后出血、感染以及吻合口狭窄发生率比较均无统计学差异(P>0.05);两组患者术后5年无病生存率比较具有统计学差异(P<0.05),且研究组患者术后1年、3年及5年累积无病生存率均高于对照组(P<0.05);两组患者术后5年总生存率比较具有统计学差异(P<0.05),且研究组患者术后1年、3年及5年累积总生存率均高于对照组(P<0.05)。结论:吉非替尼联合新辅助化疗可降低ⅢA期EGFR突变型NSCLC患者血清CEA、CA125、SF以及VEGF水平,提高患者术后无病生存率和总生存率。